Skip to main
ABSI

Absci Corp (ABSI) Stock Forecast & Price Target

Absci Corp (ABSI) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 83%
Buy 17%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Absci is poised for success with their pioneering approach of using artificial intelligence to discover and develop novel biologics. Their lead candidate, ABS-201, has shown promising results in treating hair loss and has the potential to enter the endometriosis market. While the company faces typical risks for a development-stage biotech, their strong partnerships, impressive technology platform, and unique business model make them a strong investment opportunity for long-term growth.

Bears say

Absci is a clinical-stage biotechnology company reliant on external financing and partnerships, with a lead drug that targets the competitive AGA and endometriosis markets with no guarantee of market share. There is a risk of delays due to dependence on third-party suppliers, and while Absci's platform and drug have preclinical validation, their clinical data is not expected until 2026 and 2027, respectively, leaving them far behind their competitors.

Absci Corp (ABSI) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 83% of analysts recommend a Strong Buy, 17% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Absci Corp (ABSI) Forecast

Analysts have given Absci Corp (ABSI) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Absci Corp (ABSI) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Absci Corp (ABSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.